Tvardi Therapeutics, Inc. (TVRD)
Healthcare
Biotechnology
2.10 $
+0.0%
vs. previous close
Closing price · As of: 31. Jul 2026
Who owns Tvardi Therapeutics, Inc. (TVRD)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 60.5% of the shares are freely tradable; institutional investors hold 28.9%.
Ownership Structure
Institutional ownership
Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings.
28.9%
Insiders
Share of the stock held by the executives, founders and major shareholders of the company itself.
34.6%
Float
Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders.
60.5%
Short % of float
Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices.
4.3%
Shares Outstanding
Total number of shares issued. Price times share count gives market cap.
9Mio.
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| Slate Path Capital LP | 7.51 | 704,118 | +0.0 | 03/31/2026 |
| Vanguard Group Inc | 4.53 | 424,821 | +1.3 | 12/31/2025 |
| BlackRock Inc | 4.14 | 388,075 | -0.7 | 03/31/2026 |
| Vanguard Capital Management, LLC | 3.67 | 344,708 | +0.0 | 03/31/2026 |
| American Financial Group Inc | 2.38 | 223,659 | +0.0 | 03/31/2026 |
| Geode Capital Management, LLC | 1.94 | 182,339 | +16.0 | 03/31/2026 |
| Silvercrest Asset Management Group LLC | 1.08 | 101,034 | +0.0 | 03/31/2026 |
| State Street Corp | 1.04 | 97,231 | -15.8 | 03/31/2026 |
Funds
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| Vanguard Total Stock Mkt Idx Inv | 2.75 | 258,426 | +0.0 | 04/30/2026 |
| iShares Russell 2000 ETF | 1.68 | 157,864 | +0.9 | 05/29/2026 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.